[A new antihypertensive imidazoline derivative (St 600, Fluoronidine): I. Haemodynamic investigations at rest and during exercise (author's transl)].
Treatment of 12 hypertensive patients with a new imidazoline derivative, St 600 (1.5 to 12.0 mg daily over at least 7 days) resulted in a significant lowering of the blood pressure, mostly to normal values, parallelled by a reduced heart heart rate. A significant decrease in arterial resistance was observed at rest and during exercise in 6 of the patients, whereas a slight increase or no change was recorded in the remaining 6 patients. The changes in resistance in the pulmonary circulation were analogous to those in the systematic circulation for the 2 groups, respectively. The latter half of the patients displayed a decrease in stroke volume, cardiac index and oxygen consumption. No negative inotropic effect was observed.
D000328:Adult; D000368:Aged; D000959:Antihypertensive Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001794:Blood Pressure / Q000187:drug effects; D004341:Drug Evaluation; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D007093:Imidazoles / Q000494:pharmacology*; D008297:Male; D008875:Middle Aged
D000959:Antihypertensive Agents; D007093:Imidazoles
Ein neues Antihypertensivum der Imidazolin-Reihe: 5-Flour-2-methyl-2-Imidazolidinylidenbenzamin-Monohydroechlorid (St 600, Fluronidin): I. Hämodynamische Untersuchungen in Ruhe und unter Belastung